Novan, Inc. announced that the Company has conducted its Type C meeting with the FDA regarding SB 206 for the treatment of molluscum. The purpose of the meeting… read more.
GlaxoSmithKline announced positive results from the pivotal phase III SYNAPSE study of Nucala (mepolizumab) in patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). This is the first… read more.
Biogen announced that the first patient has been treated in the global clinical study, DEVOTE . The study is designed to evaluate the safety, tolerability and potential for… read more.
The pivotal Phase III clinical trial results announced show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) from Sanofi + Regeneron ,in children aged 6-11 years with uncontrolled… read more.
Chembio Diagnostics, Inc. a leading point-of-care diagnostic company focused on infectious diseases, announced the US launch of the rapid DPP COVID-19 serological point-of-care test for the detection of… read more.
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe… read more.
OSE Immunotherapeutics announced that the primary endpoint was met in the predefined Step-1 analysis of its Phase III Atalante 1 clinical trial of Tedopi (T-lymphocyte stimulators) in HLA-A2… read more.
Xarelto ( rivaroxaban) reduced the risk of major venous thromboembolism (VTE) by about 75% in adult patients during a period of immobilization after nonmajor lower limb orthopaedic surgery,… read more.
Mallinckrodt Plc and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced that the Therapeutic Products Directorate Of Health… read more.
Bristol Myers Squibb and bluebird bio, Inc. announced the submission of their Biologics License Application (BLA) to the FDA for idecabtagene vicleucel (ide-cel; bb2121), the companies’ lead investigational… read more.
Seqirus, a global leader in influenza prevention, announced that its adjuvanted quadrivalent influenza vaccine (aQIV) – launching as Fluad Tetra – has received a positive opinion from the… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nepexto, intended for the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
